Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.75%453.77M | 1.67%128.05M | -8.80%114.55M | -1.57%98.26M | 2.23%112.91M | -24.96%461.83M | -9.34%125.95M | -14.83%125.61M | -38.40%99.82M | -33.88%110.45M |
Operating revenue | -1.75%453.77M | 1.67%128.05M | -8.80%114.55M | -1.57%98.26M | 2.23%112.91M | -24.96%461.83M | -9.34%125.95M | -14.83%125.61M | -38.40%99.82M | -33.88%110.45M |
Cost of revenue | -2.99%274.76M | -0.46%74.88M | -10.33%70.91M | -3.26%60.22M | 3.11%68.76M | -27.42%283.24M | -8.50%75.22M | -17.25%79.08M | -42.51%62.25M | -36.00%66.69M |
Gross profit | 0.23%179.01M | 4.83%53.18M | -6.21%43.65M | 1.24%38.04M | 0.89%44.15M | -20.70%178.6M | -10.55%50.73M | -10.38%46.54M | -30.10%37.57M | -30.35%43.76M |
Operating expense | 3.29%147.94M | 24.12%44.67M | 4.08%33.58M | -5.20%33.53M | -8.68%36.17M | -20.95%143.23M | -16.47%35.99M | -19.96%32.26M | -26.55%35.37M | -20.20%39.6M |
Other operating expenses | 3.29%147.94M | 24.12%44.67M | 4.08%33.58M | -5.20%33.53M | -8.68%36.17M | -20.95%143.23M | -16.47%35.99M | -19.96%32.26M | -26.55%35.37M | -20.20%39.6M |
Operating profit | -12.17%31.07M | -42.29%8.5M | -29.47%10.07M | 104.72%4.51M | 92.13%7.98M | -19.68%35.37M | 8.19%14.74M | 22.83%14.28M | -60.65%2.2M | -68.52%4.16M |
Net non-operating interest income expense | 19.84%-17.01M | 42.31%-3.04M | 43.71%-3.18M | -8.90%-6.13M | 0.21%-4.65M | -16.14%-21.22M | 9.97%-5.28M | -35.11%-5.65M | -30.23%-5.63M | -19.38%-4.66M |
Non-operating interest expense | -19.84%17.01M | -42.31%3.04M | -43.71%3.18M | 8.90%6.13M | -0.21%4.65M | 16.14%21.22M | -9.97%5.28M | 35.11%5.65M | 30.23%5.63M | 19.38%4.66M |
Other net income (expense) | ||||||||||
Income before tax | -0.68%14.06M | -42.28%5.46M | -20.15%6.89M | 52.65%-1.62M | 754.03%3.33M | -45.07%14.15M | 21.90%9.46M | 15.93%8.63M | -369.29%-3.43M | -105.48%-509K |
Income tax | -28.35%2.67M | -75.98%660K | -10.59%1.61M | 46.70%-380K | 801.80%779K | -29.70%3.73M | 120.55%2.75M | 2.85%1.8M | -301.98%-713K | -105.69%-111K |
Net income | 9.22%11.39M | -28.48%4.8M | -22.67%5.28M | 54.22%-1.24M | 740.70%2.55M | -49.05%10.43M | 3.04%6.71M | 19.96%6.83M | -395.11%-2.72M | -105.42%-398K |
Net income continuous Operations | 9.22%11.39M | -28.48%4.8M | -22.67%5.28M | 54.22%-1.24M | 740.70%2.55M | -49.05%10.43M | 3.04%6.71M | 19.96%6.83M | -395.11%-2.72M | -105.42%-398K |
Minority interest income | ||||||||||
Net income attributable to the parent company | 9.22%11.39M | -28.48%4.8M | -22.67%5.28M | 54.22%-1.24M | 740.70%2.55M | -49.05%10.43M | 3.04%6.71M | 19.96%6.83M | -395.11%-2.72M | -105.42%-398K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 9.22%11.39M | -28.48%4.8M | -22.67%5.28M | 54.22%-1.24M | 740.70%2.55M | -49.05%10.43M | 3.04%6.71M | 19.96%6.83M | -395.11%-2.72M | -105.42%-398K |
Basic earnings per share | 7.75%1.53 | -29.67%0.64 | -23.66%0.71 | 54.05%-0.17 | 780.00%0.34 | -49.29%1.42 | 2.25%0.91 | 19.23%0.93 | -384.62%-0.37 | -105.00%-0.05 |
Diluted earnings per share | 7.80%1.52 | -29.67%0.64 | -24.73%0.7 | 54.05%-0.17 | 780.00%0.34 | -49.28%1.41 | 2.25%0.91 | 20.78%0.93 | -408.33%-0.37 | -105.05%-0.05 |
Dividend per share | 0.00%0.62 | 0.00%0.155 | 0.00%0.155 | 0.00%0.155 | 0.00%0.155 | 0.00%0.62 | 0.00%0.155 | 0.00%0.155 | 0.00%0.155 | 0.00%0.155 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |